Ethereum’s institutional adoption moved sharply higher at the start of 2026, as global banks, asset managers, and fintech platforms launched new products directlyEthereum’s institutional adoption moved sharply higher at the start of 2026, as global banks, asset managers, and fintech platforms launched new products directly

Ethereum Surges in Institutional Demand As Stablecoin Supply Tops $300 Billion

2026/02/10 09:15
3분 읽기

Ethereum’s institutional adoption moved sharply higher at the start of 2026, as global banks, asset managers, and fintech platforms launched new products directly on the network.

David Walsh, Head of Enterprise at the Ethereum Foundation, said in a Feb. 9 update that January delivered one of the fastest institutional starts Ether has seen in years.

Fidelity Digital Assets introduced its own stablecoin, FIDD, on the network mainnet, while total stablecoin supply across the market climbed beyond $300 billion, with ETH holding the largest share.

Traditional finance grew with filings and investment products. Morgan Stanley filed paperwork for an ETH ETF, and Grayscale was the first US ETF provider to share staking rewards.

This is a new way for crypto yields to be introduced into traditional markets. In Europe, a set of 12 banks under Qivalis announced the launch of a euro-backed stablecoin on Ether, which is in line with Europe’s regulations under MiCA.

Tokenization Growth Signals Broader Financial Integration

In January, the use of Ether in the tokenization of real-world assets increased. The total value of tokenized commodities on the network was $5 billion, which is approximately 70% of the market in this sector.

J.P. Morgan launched a tokenized money market fund named MONY on the public Ether network with its own capital of $100 million. Ondo Finance’s total value locked on ETH increased to $1.8 billion, which is over 70% of its total activities on the platform.

Fintechs continued to scale alongside banks. Revolut’s users have staked over 60,000 ETH, indicating more mainstream participation in ETH staking. Regulators began testing infrastructure that uses Ethereum as collateral.

The US CFTC launched a pilot program that allows ETH and USDC to be used as margin collateral in derivatives markets, indicating regulators are becoming more comfortable with blockchain technology in regulated finance.

Long Ethereum Consolidation Keeps Breakout Debate Active

As institutional activity increases, Ethereum’s price remains in a state of little change. On Feb. 9, Ethereum enthusiast Poseidon stated that ETH has been trading between $2,000 and $4,000 since March 2024.

Source: X

This is part of a larger trend of sideways trading that began after the peak in 2021. Poseidon described this larger trading range as an accumulation phase, not a weakness, and likened it to gold being squeezed for years before a large breakout. The key signal that traders watch for is breaking above $4,000.

However, these forecasts are market commentary and not yet confirmed results. As of Feb. 9, Ethereum is currently trading around the middle part of its range, as it is based on price data from major trackers such as CoinMarketCap.

2026 is a possible turning point for Ethereum adoption, according to Standard Chartered, while BlackRock states that Ethereum supports 65% of tokenized assets in the market today.

Also Read: Ethereum (ETH) Derivatives Market Sees $122 Million Whale Long Trade

면책 조항: 본 사이트에 재게시된 글들은 공개 플랫폼에서 가져온 것으로 정보 제공 목적으로만 제공됩니다. 이는 반드시 MEXC의 견해를 반영하는 것은 아닙니다. 모든 권리는 원저자에게 있습니다. 제3자의 권리를 침해하는 콘텐츠가 있다고 판단될 경우, service@support.mexc.com으로 연락하여 삭제 요청을 해주시기 바랍니다. MEXC는 콘텐츠의 정확성, 완전성 또는 시의적절성에 대해 어떠한 보증도 하지 않으며, 제공된 정보에 기반하여 취해진 어떠한 조치에 대해서도 책임을 지지 않습니다. 본 콘텐츠는 금융, 법률 또는 기타 전문적인 조언을 구성하지 않으며, MEXC의 추천이나 보증으로 간주되어서는 안 됩니다.

추천 콘텐츠

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
공유하기
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
공유하기
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
공유하기
BitcoinEthereumNews2025/09/18 05:26